In COVID-19 clinical update #115, Dr. Griffin discusses croup association with infection surge, rhinovirus co-circulation in children, shedding following vaccination, high vaccine efficacy in children 6 mo-5 yr, vaccine protection for hospitalized patients, convalescent plasma as post-exposure prophylaxis, real-world effectiveness of PAXLOVID, effectiveness of PAXLOVID in reducing hospitalization, infection rebound after PAXLOVID, relapse of symptomatic infection after PAXLOVID, remdesivir and bebtelovimab fact sheets for providers, guidelines on usage of anticoagulation drugs, long covid symptoms after vaccination, excess morality in MA, infection sequelae and immunity, and post infection conditions among adults.
In COVID-19 clinical update #115, Dr. Griffin reviews cross-variant immunity without vaccination, EUA for boosters in 5-11 year olds, B.1.1.529 attack rate, scent dogs, Omicron and pets, Paxlovid, Veklury, Fluvoxamine, antigen positivity after isolation, inflammasome activation and severe disease, and GI persistence and fecal shedding.
n COVID-19 clinical update #114, Dr. Griffin discusses early treatment with ivermectin, procalcitonin not a reliable biomarker, vaccine in 6-11 year olds, FDA limits use of Janssen vaccine, does site of vaccine booster matter, sniffer dogs, monoclonals for hospitalized patients, risk assessment for public events, Paxlovid eligibility, and persistence of pediatric anosmia,
In COVID-19 clinical update #113, Dr. Griffin discusses tocilizumab use in hospitalized Patients, IL-6 inhibitors and mortality, Baricitinib in hospitalized patients, post-infection neurological sequelae, comparative effectiveness of Pfizer and Moderna vaccines, phase 2/3 study of Paxlovid, infection relapse following Paxlovid, pre-hospital administration of Remdesivir, and hospitalization with different variants.
In COVID-19 clinical update #112, Dr. Griffin reviews seroprevalence of infection-induced antibodies, Moderna filing for vaccine authorization in young children, public health impact of vaccines in US, FDA approval of first treatment for young children, phase 2 data for Sabizabulin, and post infection inflammation.
In COVID-19 clinical update #111, Dr. Griffin discusses vaccine coverage and mortality in Hong Kong, immune response to boosters in kids, hospitalization of kids, breath based diagnostic test, viral co-infections, bivalent mRNA vaccine, intramuscular Evusheld, and global long COVID.
This episode of TWiV is focused on COVID-19 vaccines and antibodies: who should get boosters, whether a variant matched mRNA vaccine is superior to a historical vaccine, and how the interval between vaccination and infection influences the quality of the antibody response.
In COVID-19 clinical update #110, Dr. Griffin covers hospital admissions during variant outbreaks, viral load in vaccinated and unvaccinated individuals, predictive capacity of symptoms in children, comparison of antigen tests, incidence of myocarditis after vaccination, steroids during replication phase, Paxlovid efficacy and safety, fluvoxamine, sabizabutin, colchicine, and prevalence of infection in Africa.
In COVID-19 clinical update #109, Daniel Griffin discusses cardiac complications after infection or vaccination, long COVID in children, fourth vaccine dose in Israel, no need for fourth vaccine dose in EU, dexamethasone dosing, immunomodulation therapy, MIS outcomes in children, US long COVID effort launched, and herd immunity.
In COVID-19 clinical update #107, Daniel Griffin reviews vaccine booster doses, at-home testing, transmission in ferrets, improving indoor air quality, trials of BCG, ivermectin, and fluvoxamine, vaccination during pregnancy, mRNA vaccines and Fc functions, anti-platelet and aspirin therapy and a trial of prone positioning.